News
-
2024-12-30
AnnJi’s AJ302 Received the 2024 National Innovation Award – A Testament to Continuous Excellence!
-
2024-05-22
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
-
2024-01-02
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
-
2023-12-12
AnnJi Invited to Meet with President Tsai as a Recipient of 2023 Bio Taiwan Awards
-
2023-08-02
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
-
2023-07-26
AnnJi Pharmaceutical Received 2023 Emerging Company of the Year
-
2023-03-22
First-In-Patient Trial of a Drug to Treat Kennedy’s Disease
-
2023-03-03
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy’s Disease
-
2023-03-02
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
-
2022-12-06
AnnJi’s AJ201 Received The National Innovation Award of 2022